Dementia is a progressive condition that slowly robs people of their ability to think and function. It is caused by a variety of brain illnesses that affect memory, thinking, behavior and the ability to perform everyday activities. Dementia can be overwhelming for people who have it and for their caregivers and families. A lack of awareness and understanding of dementia results in stigma, barriers to diagnosis and care, and negative physical, psychological, and economic effects.
Approximately 44 million people worldwide suffer from dementia. This number is expected to double by 2030 and more than triple by 2050.
Johnson & Johnson and its Janssen Pharmaceutical Companies have a strong tradition of investment in innovative science and collaborations in Alzheimer's disease. Janssen has a comprehensive Alzheimer's disease research and development program, focused on slowing or preventing disease progression. Janssen researchers are studying hallmarks of the illness – amyloid plaques, tau tangles and loss of nerve cell connections in the brain, all of which can lead to Alzheimer's dementia. Their research projects include small molecule treatments, antibodies and therapeutic vaccines. Janssen also has many current scientific collaborations in this area.